The price in value-based payment deals should by definition be justified, so why is patient cost-sharing part of the calculation? Spark covers this cost, but there is no…
A price war over anti-PD-(L)1 drugs is raging in China, less than a year after the first one was approved. When could the US see something similar?
An Icer white paper provides ammunition for both PBMs and pharma before the next Capitol Hill hearing.
Many in the biopharma sector will rue the departure of Scott Gottlieb, an FDA commissioner who pursed a permissive path for novel drugs at the US regulator. Will his…
Lilly's authorised Humalog generic price undercuts Sanofi’s copycat attack, but will cut into branded sales.
Executives were pressed to lower prices in a post-rebate world, but a broad commitment to offset rebates did not materialise.
Incredibly, a US FDA panel has left the door open for approval of Karyopharm’s selinexor in multiple myeloma, despite concerns about safety.
An increased risk of blood clots and death with Pfizer’s drug could also bode ill for newer Jak inhibitors.
Amgen has set the stage for low-hassle access to new cholesterol-lowering agents, leaving little choice for competitors.